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Epigenetic regulation shapes normal and pathologi-
cal mammalian development and physiology. Our
previous work showed that Kit RNAs injected into
fertilized mouse eggs can produce heritable epige-
netic defects, or paramutations, with relevant loss-
of-function pigmentation phenotypes, which affect
adult phenotypes in multiple succeeding generations
of mice. Here, we illustrate the relevance of para-
mutation to pathophysiology by injecting fertilized
mouse eggs with RNAs targeting Cdk9, a key regula-
tor of cardiac growth. Microinjecting fragments of
either the coding region or the related microRNA
miR-1 led to high levels of expression of homologous
RNA, resulting in an epigenetic defect, cardiac hy-
pertrophy, whose efficient hereditary transmission
correlated with the presence of miR-1 in the sperm
nucleus. In this case, paramutation increased rather
than decreased expression of Cdk9. These results
highlight the diversity of RNA-mediated epigenetic
effects and may provide a paradigm for clinical cases
of familial diseases whose inheritance is not fully
explained in Mendelian terms.
INTRODUCTION
We recently described a heritable epigenetic modification (para-
mutation) of the Kit gene of the mouse (Rassoulzadegan et al.,
2006). A mode of heredity mediated by RNA molecules was sug-
gested by the unusual accumulation of RNA in sperm and sup-
ported by the establishment of the epigenetic modification
following microinjection into one-cell embryos of either sperm
RNA of the paramutated males, or the Kit-specific microRNAs
miR-221 and miR-222. One may further consider the hereditary
transmission of an epigenetic modification as a possible cause
of familial disease predispositions. We describe here the in-
duction of hereditary cardiac hypertrophy with signs typical of
human hypertrophic cardiomyopathy (HCM) in response to
microinjection of microRNA-1 miR-1 in early embryos.962 Developmental Cell 14, 962–969, June 2008 ª2008 Elsevier Inc.Human HCM is an important heart disease with a prevalence of
1:500. It results in cardiac hypertrophy with subsequent heart fail-
ure and sudden death in a large proportion of cases (reviewed by
Maron, 2002). It is often a familial disease; predisposing muta-
tions are known in at least 13 loci, most of them encoding proteins
of the contractile apparatus. A variety of experimental models of
cardiac hypertrophy have been developed (reviewed by Sano
et al., 2002; Kulkarni et al., 2004). A major finding in the different
models was the fact that both hypertrophy and normal cardiac
development correspond to an enlargement of the cardiomyo-
cytes with increased RNA and protein synthesis. A complex of
proteins including Cdk9 and cyclin T1, and more recently, the
microRNA miR-1, have been identified as major responsible fac-
tors for cardiac growth. The protein complex including Cdk9 and
cyclin T1 phosphorylates the carboxyterminal peptide of RNA
polymerase II (RNAPII), and a regulatory RNA (7SK RNA) and
other proteins (HEXIM) modulate the activity of the complex; mi-
croRNA miR-1 is supposed to regulate Cdk9 expression directly.
Also, an important regulatory role of miR-1 in cardiac and skeletal
muscle development and function has been recently reported
(Kwon et al., 2005; Sokol and Ambros, 2005; Zhao et al., 2005;
Chen et al., 2006; Rao et al., 2006; Sayed et al., 2007; Tatsuguchi
et al., 2007; Zhao et al., 2007).
RESULTS
Injection of MicroRNA miR-1 in the One-Cell Embryo
Results in Early Appearance of Cardiac Hypertrophy
Mice born after miR-1 injection into fertilized oocytes, designated
miR-1*, showed increased size of the hearts compared with
those of controls born after microinjection of unrelated RNA (Fig-
ure 1A). Heart weights relative to body weights were increased in
average by 30%, whereas relative brain weights were compara-
ble to those of control animals (Figures 1B–1D). Histological anal-
ysis revealed a marked increase in the size of cardiomyocytes
(Figures 1E–1G), similar to the enlargement of cells and nucleus
described in human cardiac hypertrophy (Maron, 2002; Kulkarni
et al., 2004; Koda et al., 2006). Histological analyses of kidney,
liver, and muscle sections (M. tibialis anterior) showed no obvious
differences between miR-1* and control animals, suggesting a
heart-specific effect (Figure S1, see the Supplemental Data avail-
able with this article online). The increase in both heart weight and
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tribution, which, contrary to that of the controls, was clearly not
normal, but shifted toward the high values (Figures 1B and 1G).
Such an inherent quantitative variation is a known characteristic
of the plant paramutation (‘‘rheostat effect;’’ Chandler, 2007)
and was also observed in the Kit* epigenetic variation (Rassoul-
zadegan et al., 2006). TUNEL labeling in the adult heart evidenced
an important fraction of positive cardiomyocytes (Figures 1H and
1I), also observed in human cardiac hypertrophy, in which case it
was assumed to reflect increased DNA repair activity rather than
apoptotic cell death (Koda et al., 2003).
Ultrastructural analysis (Figure 1J) showed marked abnormal-
ities in miR-1* hearts including mitochondrial disorganization and
abnormalities of the cristae structure, myofibrillar disorganiza-
tion, sarcomere shrinkage and disintegration, loss of alignment
of the myofibrils, and Z-disc irregularities, which are typical signs
of human HCM (Fananapazir et al., 1993).
Abnormal Development of the Embryonic Heart
Abnormal growth of the ventricular wall in miR-1* mice was
initiated during embryonic development. At embryonic day
18.5 (E18.5), the hearts showed an increase in size as compared
with mock-injected embryos carried by the same foster mothers,
with the same characteristic increase in cell size as in the adult
(Figure S2).
To determine the effectors of the epigenetic modification in the
embryonic heart, we performed quantitative RT-PCR, immuno-
histochemistry, and western blot assays of the expression of
the major effectors of cardiomyocyte growth: miR-1 itself and
the Cdk9-cyclin T1 kinase, as well as the associated regulatory
elements, 7SK RNA and HEXIM proteins. While miR-1 RNA
levels were not changed significantly (Figure 2A), Cdk9 RNA
levels were on average twice those of the control embryos at
E18.5 (Figure 2B), and were also slightly elevated in hearts of
adult miR-1* animals (data not shown). The increase in Cdk9 in
the embryonic hearts was even more pronounced at the protein
level (Figures 2C–2E). No significant differences were detected
for cyclin T1, 7SK RNA, and HEXIM protein (data not shown).
As expected from the augmented level of Cdk9, phosphorylation
of RNAPII was evidenced in miR-1* mice by an increase in the
amount of the phosphorylated form of the protein in the embry-
onic heart (Figure 2D). Interestingly, the elevated kinase activity
was noticeable only during embryonic development and not in
the adult heart.
Because Cdk9 mRNA has been identified as a putative target
of miR-1 by in silico analysis (http://microrna.sanger.ac.uk/), the
immediate question was whether upregulation of Cdk9 could re-964 Developmental Cell 14, 962–969, June 2008 ª2008 Elsevier Incsult from one of the known regulatory activities of the microRNA.
A series of recent reports has evidenced a negative regulation of
cardiac development by miR-1 (Zhao et al., 2005, 2007; Chen
et al., 2006; Nakajima et al., 2006). Cardiac hypertrophy in
miR-1* animals would thus be expected to result from a downre-
gulation of the microRNA. This, however, seems not to be the
case, because no significant change in miR-1 expression was
detected (Figure 2A). RNAs encoding the regulatory Ago and
Dicer proteins were either unchanged (Ago2 and 4, Dicer) or
slightly elevated (Ago1 and 3) (data not shown). Furthermore, ex-
pression of the transcriptional factor Hand2, a well-documented
target of miR-1 (Zhao et al., 2005), was similar. Along the same
line, levels of the RNAs encoding clathrin (Cltc), E2F5, Fyn, phos-
pholipase A2 (Pla2g5), transgelin (Tagln2), thymosin (Tmsb4),
and acetyl-Coenzyme A acyltransferase 2 (Acaa2), all predicted
targets of miR-1, were either slightly reduced (Igf1, Tmsb4,
Acaa2) or unaffected (Cltc, E2F5, Fyn, Pla2g5, Tagln2) (data
not shown). Given the current results, we assume that the epige-
netic modification does not result from a direct regulation by one
of the known translational controls exerted by the microRNA.
Induction of Epigenetic Cardiac Hypertrophy
by Fragments of the Cdk9 Coding Sequence
in the Early Embryo
It is likely that the effect of RNA in the one-cell embryo reveals
a distinct, still unknown mechanism, because microinjection of
RNA oligonucleotides reproducing short (20 nt) segments of
the Cdk9 coding region induced hereditary epigenetic cardiac
hypertrophy. Based on our previous observation that the Kit* epi-
genetic state was efficiently induced by fragmented Kit RNA
from heterozygotes, a mixture of two 20-nt oligoribonucleotides
with sequences randomly chosen in Cdk9 mRNA (see Experi-
mental Procedures) was microinjected into fertilized eggs. As
shown in Figure 3, E18.5 embryos grown from the injected
oocytes showed cardiac hypertrophy characteristic of the
miR-1* paramutants (Figures 3A–3C). This was accompanied
by increased Cdk9 expression and enhanced phosphorylation
of RNAPII (Figure 3D). As in miR-1* animals, hypertrophy in the
embryos, which showed significant cell enlargement and exten-
sive TUNEL staining, appeared to be sufficient for maintaining
the cardiac phenotype in the adult (Figures 3E–3J).
Efficient Hereditary Transmission
and Characterization of the Progeny
Cardiac hypertrophy was inherited in crosses of either male or
female miR-1* parents with normal partners (Figure 4). In each
generation, about 90% of the progenies had enlarged hearts,Figure 1. Adult 3-Month-Old miR-1* Mice Present a Concentric Heart Hypertrophy
(A) Hypertrophic development of the ventricular wall. Left, a control mouse heart; right, the heart of a miR-1* mouse. Scale bars: 100 mm.
(B) Body and heart weights of individual miR-1* and control animals.
(C and D) Mean values of heart/body (C) and brain/body (D) weight ratios in adult miR-1* (n = 20) and control (n = 21) mice.
(E) High magnifications of heart sections from control and miR-1* animals show the increased cardiomyocyte diameter in the miR-1* mice. Scale bars: 25 mm.
(F) Mean values of cardiomyocyte diameters.
(G) Distribution of cardiomyocyte diameters. Note the shift of the cell size to larger diameters in the miR-1* mice.
(H and I) Increased apoptosis in miR-1* versus control hearts. Five heart sections from each animal (with groups of three controls and three miR-1* mice) were
analyzed by TUNEL staining, and TUNEL-positive cells (DAB substrate, brown color) were counted. Scale bars: 50 mm.
(J) Electron microscopy examination of the miR-1* hearts revealed typical signs of hypertrophic cardiomyopathy. Left, the morphology of a control mouse heart;
right, disarranged morphology in the miR-1* heart, with myofibrillar disorganization (crosses), sarcomere shrinkage and disintegration (arrow), mitochondrial
disorganization and abnormalities (cristae structure, star), and the irregularity of Z-discs (arrowheads). Scale bars: 2 mm. ***p < 0.001..
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with the parental heart size. The intrinsic variability typical of par-
amutation already noted at the molecular level (rheostat effect) is
most obvious when considering inheritance patterns (Figure 4A).
The extreme cases involved one of the founders exhibiting an ap-
parently normal heart size but generating an extensively modi-
fied offspring, and the converse for some of the most affected in-
dividuals. Heart hypertrophy was transmitted in crosses with
normal partners for at least three generations as indicated by
increased heart-to-body weight ratios, enlarged cell diameters
Figure 2. Cdk9 Expression Is Increased in Embryonic miR-1* Hearts
(A and B) Quantitative RT-PCR analysis of the levels of miR-1 (A) and Cdk9
RNA (B) in the hearts of miR-1* and control embryos at E18.5.
(C) Immunohistochemical detection of the Cdk9 protein in paraffin sections
showed a highly increased expression in the cardiomyocytes of the miR-1*
hearts (right). Photomicrographs were taken from the central part of the inter-
ventricular septum. Scale bars: 50 mm.
(D) Western blot analysis of Cdk9 expression in E18.5 hearts. Increased Cdk9
expression in miR-1* hearts correlated with an increase in the phosphorylated
form of RNA polymerase II (upper bands); the lower bands correspond to the
nonphosphorylated protein. a-tubulin served as an internal standard. Roman
numbers indicate the control and miR-1*-injected embryos grown in the
same foster mother (see Experimental Procedures).
(E) Quantification of the western blot bands for Cdk9 normalized to a-tubulin
(n = 9, each). ***p < 0.001.D(Figures 4B–4D), higher numbers of TUNEL-positive cells, and
increased Cdk9 protein expression and phosphorylation of
RNAPII (Figure S3).
RNA Accumulation in Sperm
As in the Kit* paramutated and Kit heterozygotes, RNA accumu-
lation was evidenced in miR-1* spermatozoa by electron micros-
copy after EDTA reverse staining (Figures 4E–4H). Quantitative
RT-PCR and northern blot assays performed on RNA from
miR-1* epididymal sperm were negative for Cdk9, but evidenced
miR-1 sequences in minute amounts, which were not detectable
among the traces of RNA in extracts of the control normal sperm
(Figures 4I and 4J). Considering that cardiac hypertrophy in the
founders was initiated by RNA transfer to the fertilized egg,
sperm RNA appears as a likely candidate as the signal responsi-
ble for paternal inheritance.
DISCUSSION
Our observations extend the notion of paramutation in the
mouse to a well-documented pathophysiological state. Its initial
induction involves a modification of the expression of a critical
RNA. Subsequently, it is inherited both paternally and mater-
nally, and associated with the accumulation of RNA in the sperm
head. It is induced de novo by exposure of the early embryo to
the cognate RNA and microRNA. The mechanisms leading to
a modified expression in somatic tissues, as well as the primary
event modifying the one-cell embryo, remain to be explored in
molecular terms. Induction of cardiac hypertrophy by micro-
RNAs seems to be unique to miR-1, since no comparable pheno-
type was observed in a series of microinjection experiments
involving miR-221, miR-222 (Rassoulzadegan et al., 2006),
miR-124, miR-16, and miR-92 (unpublished data). Increased
expression of Cdk9, a critical regulator of cardiac growth (Sano
et al., 2002), appears as the likely cause of cardiac hypertrophy
in miR-1* mice. A microRNA-mediated regulation does not agree
with either the unchanged levels of miR-1 or the lack of effect on
other targets of the microRNA. Moreover, what appears to be
essentially the same effect is seen after microinjection of other
Cdk9-related sequences, this time segments of the coding
region. One would thus have to consider that induction of epige-
netic states by microRNAs involves still unknown molecular
mechanisms that are distinct from their known activity in the
control of mRNA stability and translation. Our current under-
standing of microRNA functions is clearly not complete yet.
Recent reports describe microRNA-dependent upregulation of
gene expression by translation activation (Vasudevan et al.,
2007; Buchan and Parker, 2007), a process that does not by itself
account for the increase in Cdk9 mRNA in the miR-1* paramu-
tants. We note that, in addition to the mouse and the plant para-
mutation, recent advances in the analyses of various epigenetic
changes (X chromosome inactivation, silencing of imprinted
genes, genome rearrangement in ciliates) concurred regarding
the involvement of RNA determinants and still essentially
unknown mechanisms (Masui and Heard, 2006; Pauler et al.,
2007; Nowacki et al., 2007).
Establishment of the epigenetic state so far appears as
a unique property of the early embryo, as a consequence of
a modification of the RNA profile of the locus, either by RNAevelopmental Cell 14, 962–969, June 2008 ª2008 Elsevier Inc. 965
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(A) Mean values of heart/body weight ratios in Cdk9-RNA-injected and control embryos at E18.5.
(B) Representative photomicrographs from control (left) and Cdk9* (right) heart sections. Note the increased cardiomyocyte diameter in Cdk9* embryos.
(C) Mean values of the cardiomyocyte diameter.
(D) Western blot analysis of Cdk9 and RNA polymerase II expression in E18.5 hearts; a-tubulin served as an internal standard; roman numbers indicate individual
animals.
(E) Mean values of heart/body weight ratios in adult (3-month-old) Cdk9* and control mice.
(F) High-power magnifications of heart sections from adult control and Cdk9* animals. Note the increased cardiomyocyte diameter in the adult Cdk9* mice.
(G) Mean values of cardiomyocyte diameters.
(H) Distribution of cardiomyocyte diameters.
(I) TUNEL labeling is increased in Cdk9* versus control hearts. Three heart sections from each animal (in groups of three controls and three Cdk9* mice) were
analyzed by TUNEL staining, and TUNEL-positive cells (brown color) were counted.
(J) Representative photomicrographs for the TUNEL-stained heart sections.
Scale bars: 50 mm. ***p < 0.001.microinjection or upon fertilization by the RNA-loaded sperm of
paramutant males. A surveillance mechanism thus appears to
be acting, which may share some of its components with the
efficient quality controls of the messenger RNAs in differentiated966 Developmental Cell 14, 962–969, June 2008 ª2008 Elsevier Inc.mammalian cells (reviewed by Isken and Maquat, 2007). A depar-
ture from the normal distribution of transcripts results in the
imprinting of a permanent epigenetic mark. An increase in the
levels of microRNA and mRNA sequences, abnormal intracellular
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ceived as dangerous and initiate a hereditary program for pro-
tecting the embryos from abnormal expression of important
genes.
Definitely establishing the nature of the epigenetic mark re-
sponsible for the transgenerational stability of the pathological
phenotype remains a matter for further studies. Quantitative
RT-PCR assays detected miR-1 sequences in the sperm of
founders, which efficiently transmit the epigenetic alteration,
suggesting that they may be the signal that induces the
Figure 4. Cardiac Hypertrophy in miR-1*
Mice Is Inherited over At Least Three Gener-
ations and RNA Is Accumulated in Sperm
(A) Efficiency of transmission and extent of hyper-
trophy in the progeny of crosses of either male
(black circles) or female (white circles) miR-1*
mice. The parental heart/body weight ratios are
entered on the horizontal axis and, for each parent,
individual values in a litter are shown on the vertical
axis. The broken lines correspond to the average
value for control animals.
(B) Mean values of heart/body weight ratios
in adult (6-month-old) animals of the miR-1* F1
(n = 147), F2 (n = 36), and F3 (n = 9) generation
versus control animals (n = 21).
(C) Mean values of the cardiomyocyte diameters.
(D) Distribution of cardiomyocyte diameters. Note
the persisting shift to larger cell diameters in the
miR-1* progenies. Scale bars: 50 mm. ***p < 0.001.
(E–H) EDTA regressive staining of epididymis sec-
tions from miR-1* animals (E and F). Control stain-
ings were performed after incubation with RNase
(G) and DNase (H). Scale bars: 1 mm.
(I) Quantitative RT-PCR determination of miR-1
relative to GAPDH in sperm from miR-1* animals
and controls. The logarithmic scaling of the verti-
cal axis was chosen to visualize the very low
values of miR-1 RNA in sperm of control animals.
(J) miR-1 RNA expression in sperm of controls and
miR-1* progenies of the first and second genera-
tions (F1 and F2) detected by northern blot hybrid-
ization. ***p < 0.001.
pathological development in the progeny.
Among other possible marks, the methyl-
ation state of DNA in and around the
Cdk9 and miR-1 loci is currently being
analyzed, but results are so far consis-
tently negative (data not shown). It must
be mentioned, however, that in the case
of the B1-B’ paramutation of maize,
changes in methylation were observed
in a regulatory element 100 kb away
from the gene. Given the paucity of cur-
rent data on Cdk9 transcription and its
possible regulatory elements, large-scale
exploratory approaches will have to be
considered.
On the basis of the murine models, one
may now consider a possible contribution
of heritable epigenetic changes to patho-
physiological predispositions. It is of interest in this respect to
consider that about half of the human hereditary cardiomyopa-
thies are familial cases (Maron, 2002). Mutations in at least 13
loci, most of them encoding sarcomeric proteins, have been
identified in the affected families. The lack of a clear molecular
link between these alterations and the control of cardiomyocyte
growth, as well as the variability in penetrance among individuals
with the same mutation, had led to the suspicion that other, still
unknown factors are involved. Based on our present results, the
mouse models suggest the possible establishment and familialDevelopmental Cell 14, 962–969, June 2008 ª2008 Elsevier Inc. 967
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quences. Given the relatively important load of RNA in human
sperm (Ostermeier et al., 2004), it is tempting to speculate about
a possible role of these mechanisms in human pathology and
heredity.
EXPERIMENTAL PROCEDURES
RNA Microinjection in Fertilized Eggs
RNA microinjection into B6D2 fertilized eggs after normal ovulation was
performed by the same method as DNA transgenesis (Hogan et al., 1994). Oli-
goribonucleotides (Sigma-Proligo) were miR-1 UGGAAUGUAAAGAAGUAUG
UAU and two oligoribonucleotides with sequences from Cdk9 mRNA Cdk9-
1332 (GAUUUUCUCCUCCAGUACAUAU) and Cdk9-1662 (GUUAAGUUUAG
AGACAUUCC). As controls, fertilized eggs were microinjected with a 20-nt
RNA oligonucleotide with a sequence derived from the mouse Sycp1 coding
sequence. For studies of embryos during gestation, the control and miR-1-mi-
croinjected embryos were separately reimplanted in the left and right uterine
horns of the same foster mother. Investigations were conducted in accordance
with French and European rules for the care and use of laboratory animals.
Immunohistochemical Analysis
Paraffin sections (5 mm) were stained with hematoxylin and eosin. The mean
cardiomyocyte diameter was determined by measuring 30 cells from three in-
dependent sections of three embryos, using an epifluorescence microscope
connected to a digital camera and Spot software (Universal Imaging Corp.).
Staining for Cdk9 was performed using a mouse monoclonal Cdk9 antibody
(D-7, sc-13130, Santa Cruz Biotechnology) in a 1:100 dilution; subsequent an-
tigen detection was performed with the M.O.M. Kit (PK-2200, Vector Labora-
tories) and DAB (SK-4100, Vector Laboratories) as a substrate. Nuclei were
counterstained with hematoxylin.
SDS-PAGE and Western Blot
Total heart lysates from E18.5 embryos were prepared, electrophoresed, and
blotted. The following antibodies and solutions were used for immunodetec-
tion: polyclonal anti-Cdk9 antibody from rabbit (H-169, sc-8338, Santa Cruz
Biotechnology) in a 1:500 dilution in PBS, 2.5% Blotto, 0.05% Tween-20, poly-
clonal anti-RNAPII from rabbit (N-20, sc-899, Santa Cruz Biotechnology),
1:500; monoclonal anti-a-tubulin from mouse (T6199, Sigma), 1:2000; peroxi-
dase-coupled goat anti-rabbit secondary antibody (Santa Cruz Biotechnol-
ogy), 1:10,000; and peroxidase-coupled rabbit anti-mouse secondary antibody
(Santa Cruz Biotechnology), 1:10,000.
Electron Microscopy
RNA-protein complexes were visualized by the EDTA regressive staining
technique (Biggiogera and Fakan, 1998), with control staining performed after
incubation with RNase (RNase I, DNase free, USB, cat. number 27-0323-01)
and DNase (DNase I, RQ1, Promega, cat. number M610A). For ultrastructural
analysis of cardiac muscle, small pieces were fixed in 1.6% glutaraldehyde in
0.1M phosphate buffer (pH 7.5) then washed with 0.1M cacodylate buffer (pH
7.5) and postfixed with 1% osmium tetroxide in the same buffer. Samples were
embedded in epoxy resin. Thin sections were contrasted with uranyl acetate
and lead citrate and observed with a Philips CM12 electron microscope fitted
with a CCD camera (Morada, Olympus SIS).
Quantitative RT-PCR
RT-PCR was performed with 2 mg of total RNA as described elsewhere (Wag-
ner et al., 2006). Real-time PCR was performed on the Light Cycler Instrument
(Roche Diagnostics) using the Platinum SYBR Green kit (Invitrogen). miR-1 de-
terminations were performed with the Taqman MicroRNA Assay (Applied Bio-
systems) hsa-miR-1. Primer sequences are listed in Table S1, available online.
RNA Preparation from Epididymal Sperm
and Northern Blot Hybridization
Sperm was collected from epididymis by squeezing. The cell suspension was
centrifuged at 1000 rpm for 5 min and the supernatant containing the sperma-
tozoa was centrifuged at 3000 rpm for 15 min. To reduce contamination of968 Developmental Cell 14, 962–969, June 2008 ª2008 Elsevier Incsomatic cells, the pellet was submitted to hypotonic shock by resuspension
in water (250 ml), followed by the addition of 15 ml of PBS. Finally, the suspen-
sion was centrifuged at 3000 rpm for 15 min and resuspended in 1M NaCl, 3.3
mM dithiotreitol. RNA was then extracted by the TRIzol procedure (Invitrogen).
Northern blot analysis was performed as described (Lee and Ambros, 2001).
Briefly, total RNA extracted from the spermatozoa collected from three males
(approximately 40 millions cell equivalent per lane) was loaded onto a 15%
denaturing polyacrylamide gel and electrophoresed until the bromophenol
blue marker reached the bottom of the gel. The separated RNA was electro-
transferred to a Hybond N+ membrane (Amersham). Hybridization was carried
out in the presence of 32P-end-labeled DNA oligonucleotide probe corre-
sponding to the complementary mature miR-1 sequence.
TUNEL Labeling of Apoptotic Cells
Apoptotic cells were detected by TUNEL staining in paraffin-embedded heart
sections using the In situ Cell Death Detection Kit (Roche Molecular Biochem-
icals) as described previously (Wagner et al., 2005). Five tissue sections were
analyzed from three different controls and three miR-1* or Cdk9* animals.
Statistics
Data are expressed as means ± SEM. ANOVA with the Bonferroni test as post
hoc test was used versus control. Differences between two groups were
tested using the Mann-Whitney test for nonparametric samples. A p value
less than 0.05 was considered statistically significant.
SUPPLEMENTAL DATA
Supplemental Data include three figures and one table and are available with
this article online at http://www.developmentalcell.com/cgi/content/full/14/6/
962/DC1/.
ACKNOWLEDGMENTS
We thank C. Vannetti, L. Martin, M. Radjkhumar, F. Millot, F. Paput, M. Cutajar,
and T. Amine for skilled technical assistance. The work was made possible by
grants to M.R. from Ligue Nationale Contre le Cancer (France) as ‘‘Equipe La-
bellise´e’’ and from ‘‘Agence Nationale de la Recherche’’ (grant ANR-06-BLAN-
0226 PARAMIR). N.W. was the recipient of a fellowship from the Fondation de
France and was supported financially by A. Schedl, and H.G. was the recipient
of a scholarship from Shahiid Beheshti University of Medical Sciences, Iran.
Received: August 17, 2007
Revised: December 14, 2007
Accepted: March 18, 2008
Published: June 9, 2008
REFERENCES
Biggiogera, M., and Fakan, S. (1998). Fine structural specific visualization of
RNA on ultrathin sections. J. Histochem. Cytochem. 46, 389–395.
Buchan, J.R., and Parker, R. (2007). Molecular biology. The two faces of
miRNA. Science 318, 1877–1878.
Chandler, V.L. (2007). Paramutation: from maize to mice. Cell 23, 641–645.
Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond,
S.M., Conlon, F.L., and Wang, D.Z. (2006). The role of microRNA-1 and micro-
RNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38,
228–233.
Fananapazir, L., Dalakas, M.C., Cyran, F., Cohn, G., and Epstein, N.D. (1993).
Missense mutations in the beta-myosin heavy-chain gene cause central core
disease in hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 90,
3993–3997.
Hogan, B., Costantini, F., and Lacy, L. (1994). Manipulating the Mouse Em-
bryo – A Laboratory Manual, Second Edition (Cold Spring Harbor, NY: Cold
Spring Harbor Laboratory).
Isken, O., and Maquat, L.E. (2007). Quality control of eukaryotic mRNA: safe-
guarding cells from abnormal mRNA function. Genes Dev. 21, 1833–1856..
Developmental Cell
RNA-Mediated Paramutation of Heart DevelopmentKoda, M., Takemura, G., Kanoh, M., Hayakawa, K., Kawase, Y., Maruyama, R.,
Li, Y., Minatoguchi, S., Fujiwara, T., and Fujiwara, H. (2003). Myocytes positive
for in situ markers for DNA breaks in human hearts which are hypertrophic, but
neither failed nor dilated: a manifestation of cardiac hypertrophy rather than
failure. J. Pathol. 199, 229–236.
Koda, M., Takemura, G., Okada, H., Kanoh, M., Maruyama, R., Esaki, M., Li,
Y., Miyata, S., Kanamori, H., Li, L., et al. (2006). Nuclear hypertrophy reflects
increased biosynthetic activities in myocytes of human hypertrophic hearts.
Circ. J. 70, 710–718.
Kulkarni, P.A., Sano, M., and Schneider, M.D. (2004). Phosphorylation of RNA
polymerase II in cardiac hypertrophy: cell enlargement signals converge on
cyclin T/Cdk9. Recent Prog. Horm. Res. 59, 125–139.
Kwon, C., Han, Z., Olson, E.N., and Srivastava, D. (2005). MicroRNA1 influ-
ences cardiac differentiation in Drosophila and regulates Notch signaling.
Proc. Natl. Acad. Sci. USA 102, 18986–18991.
Lee, R.C., and Ambros, V. (2001). An extensive class of small RNAs in Caeno-
rhabditis elegans. Science 294, 862–864.
Maron, B.J. (2002). Hypertrophic cardiomyopathy: a systematic review. JAMA
287, 1308–1320.
Masui, O., and Heard, E. (2006). RNA and protein actors in X-chromosome
inactivation. Cold Spring Harb. Symp. Quant. Biol. 71, 419–428.
Nakajima, N., Takahashi, T., Kitamura, R., Isodono, K., Asada, S., Ueyama, T.,
Matsubara, H., and Oh, H. (2006). MicroRNA-1 facilitates skeletal myogenic
differentiation without affecting osteoblastic and adipogenic differentiation.
Biochem. Biophys. Res. Commun. 350, 1006–1012.
Nowacki, M., Vijayan, V., Zhou, Y., Schotanus, K., Doak, T.G., and Landweber,
L.F. (2007). RNA-mediated epigenetic programming of a genome-rearrange-
ment pathway. Nature 451, 153–158.
Ostermeier, G.C., Miller, D., Huntriss, J.D., Diamond, M.P., and Krawetz, S.A.
(2004). Reproductive biology: delivering spermatozoan RNA to the oocyte.
Nature 429, 154.
Pauler, F., Koerner, M., and Barlow, D. (2007). Silencing by imprinted noncod-
ing RNAs: is transcription the answer? Trends Genet. 23, 284–292.
Rao, P.K., Kumar, R.M., Farkhondeh, M., Baskerville, S., and Lodish, H.F.
(2006). Myogenic factors that regulate expression of muscle-specific micro-
RNAs. Proc. Natl. Acad. Sci. USA 103, 8721–8726.DRassoulzadegan, M., Grandjean, V., Gounon, P., Vincent, S., Gillot, I., and Cu-
zin, F. (2006). RNA-mediated non-Mendelian inheritance of an epigenetic
change in the mouse. Nature 441, 469–474.
Sano, M., Abdellatif, M., Oh, H., Xie, M., Bagella, L., Giordano, A., Michael,
L.H., DeMayo, F.J., and Schneider, M.D. (2002). Activation and function of
cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-
cell hypertrophy. Nat. Med. 8, 1310–1317.
Sayed, D., Hong, C., Chen, I.Y., Lypowy, J., and Abdellatif, M. (2007). Micro-
RNAs play an essential role in the development of cardiac hypertrophy. Circ.
Res. 100, 416–424.
Sokol, N.S., and Ambros, V. (2005). Mesodermally expressed Drosophila
microRNA-1 is regulated by Twist and is required in muscles during larval
growth. Genes Dev. 19, 2343–2354.
Tatsuguchi, M., Seok, H.Y., Callis, T.E., Thomson, J.M., Chen, J.F., Newman,
M., Rojas, M., Hammond, S.M., and Wang, D.Z. (2007). Expression of micro-
RNAs is dynamically regulated during cardiomyocyte hypertrophy. J. Mol. Cell.
Cardiol. 42, 1137–1141.
Vasudevan, S., Tong, Y., and Steitz, J.A. (2007). Switching from repression to
activation: microRNAs can up-regulate translation. Science 318, 1931–1934.
Wagner, N., Wagner, K.D., Theres, H., Englert, C., Schedl, A., and Scholz, H.
(2005). Coronary vessel development requires activation of the TrkB neurotro-
phin receptor by the Wilms’ tumor transcription factor Wt1. Genes Dev. 19,
2631–2642.
Wagner, N., Wagner, K.D., Scholz, H., Kirschner, K.M., and Schedl, A. (2006).
Intermediate filament protein nestin is expressed in developing kidney and
heart and might be regulated by the Wilms’ tumor suppressor Wt1. Am. J.
Physiol. Regul. Integr. Comp. Physiol. 291, R779–R787.
Zhao, Y., Samal, E., and Srivastava, D. (2005). Serum response factor regu-
lates a muscle-specific microRNA that targets Hand2 during cardiogenesis.
Nature 436, 214–220.
Zhao, Y., Ransom, J.F., Li, A., Vedantham, V., von Drehle, M., Muth, A.N.,
Tsuchihashi, T., McManus, M.T., Schwartz, R.J., and Srivastava, D. (2007).
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice
lacking miRNA-1–2. Cell 129, 303–317.evelopmental Cell 14, 962–969, June 2008 ª2008 Elsevier Inc. 969
